Digestive Remedies Market Analysis in Japan

Digestive Remedies Market Analysis in Japan Add to your bookmarks!

$ 898 - May 2012 - by Euromonitor International - 42

Summary

Table of Contents

View Report

Search Inside

Data Series

Industry

Drug and Medication

Country

Japan

Keywords

Remedy
Medication
Laxative

Value sales of digestive remedies declined by 2% in 2011. The continued economic downturn and consumers’ reduced dining at restaurants and bars discouraged sales of digestive remedies. Japanese companies often organise “nomikai” or drinking sessions to meet with clients and to strengthen the bonds among colleagues. However, after the March 2011 earthquake, many companies officially restrained from “nomikai” out of respect to the sufferers in the Tohoku region. During spring, it is common for...

Euromonitor International's Digestive Remedies in Japan report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2007-2011, allowing you to identify the sectors driving growth. Forecasts to 2016 illustrate how the market is set to change.

Product coverage: Diarrhoeal Remedies, IBS Treatments, Indigestion and Heartburn Remedies, Laxatives, Motion Sickness Remedies, Paediatric Digestive Remedies.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Digestive Remedies market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.

DIGESTIVE REMEDIES IN JAPAN
Euromonitor International
May 2012

LIST OF CONTENTS AND TABLES

Headlines
Trends
Switches
Competitive Landscape
Prospects
Category Data
Table 1 Sales of Digestive Remedies by Category: Value 2006-2011
Table 2 Sales of Digestive Remedies by Category: % Value Growth 2006-2011
Table 3 Digestive Remedies Company Shares by Value 2007-2011
Table 4 Digestive Remedies Brand Shares by Value 2008-2011
Table 5 Forecast Sales of Digestive Remedies by Category: Value 2011-2016
Table 6 Forecast Sales of Digestive Remedies by Category: % Value Growth 2011-2016
Daiichi Sankyo Healthcare Co Ltd in Consumer Health (japan)
Strategic Direction
Key Facts
Summary 1 Daiichi Sankyo Healthcare Co Ltd: Key Facts
Summary 2 Daiichi Sankyo Healthcare Co Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
Summary 3 Daiichi Sankyo Healthcare Co Ltd: Competitive Position 2011
Otsuka Pharmaceutical Co Ltd in Consumer Health (japan)
Strategic Direction
Key Facts
Summary 4 Otsuka Pharmaceutical Co Ltd: Key Facts
Summary 5 Otsuka Pharmaceutical Co Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
Summary 6 Otsuka Pharmaceutical Co Ltd: Competitive Position 2011
Rohto Pharmaceutical Co Ltd in Consumer Health (japan)
Strategic Direction
Key Facts
Summary 7 Rohto Pharmaceutical Co Ltd: Key Facts
Summary 8 Rohto Pharmaceutical Co Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
Summary 9 Rohto Pharmaceutical Co Ltd: Competitive Position 2011
Sato Pharmaceutical Co Ltd in Consumer Health (japan)
Strategic Direction
Key Facts
Summary 10 Sato Pharmaceutical Co Ltd: Key Facts
Summary 11 Sato Pharmaceutical Co Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
Summary 12 Sato Pharmaceutical Co Ltd: Competitive Position 2011
Taisho Pharmaceutical Co Ltd in Consumer Health (japan)
Strategic Direction
Key Facts
Summary 13 Taisho Pharmaceutical Co Ltd: Key Facts
Summary 14 Taisho Pharmaceutical Co Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
Summary 15 Taisho Pharmaceutical Co Ltd: Competitive Position 2011
Takeda Pharmaceutical Co Ltd in Consumer Health (japan)
Strategic Direction
Key Facts
Summary 16 Takeda Pharmaceutical Co Ltd: Key Facts
Summary 17 Takeda Pharmaceutical Co Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
Summary 18 Takeda Pharmaceutical Co Ltd: Competitive Position 2011
Executive Summary
High Pollen Levels Push Up Sales of Anti-pollen Positioned Products
March Earthquake Has Limited Impact on Consumer Health Industry
OTC Switch Creates A Major Hit Product - Loxonin S
Collagen Becomes A Beauty Catalyst Among Female Consumers
Competition Poses A Threat To Sales of Tonics and Bottled Nutritive Drinks
Key Trends and Developments
High Pollen Levels in 2011
Rising National Debt and Potential for OTC Switches
Delivery Service by Parapharmacies/drugstores
Electronic Tracking of Customer Medication Usage
Increasing Non-store Retailing Channel Sales
Market Indicators
Table 7 Consumer Expenditure on Health Goods and Medical Services 2006-2011
Table 8 Life Expectancy at Birth 2006-2011
Market Data
Table 9 Sales of Consumer Health by Category: Value 2006-2011
Table 10 Sales of Consumer Health by Category: % Value Growth 2006-2011
Table 11 Consumer Health Company Shares 2007-2011
Table 12 Consumer Health Brand Shares 2008-2011
Table 13 Penetration of Private Label by Category 2006-2011
Table 14 Sales of Consumer Health by Distribution Format: % Analysis 2006-2011
Table 15 Sales of Consumer Health by Category and Distribution Format: % Analysis 2011
Table 16 Forecast Sales of Consumer Health by Category: Value 2011-2016
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2011-2016
Appendix
OTC Registration and Classification
Consumer Healthcare Registration
Consumer Healthcare Advertising
Consumer Healthcare Packaging
Consumer Healthcare Distribution
Regulation of Japanese Traditional Herbal Remedies (kampo)
Vitamins and Dietary Supplements Registration and Classification
Self-medication/self-care and Preventative Medicine
Switches
Summary 19 OTC Switches 2009-2011
Definitions
Sources
Summary 20 Research Sources

Drug and Medication in Japan

Japan Patented Drug Sales, Us$bn

$ 250
Industry data
January 2013

Yearly, From 2002 To 2021
By Business Monitor International
Source: Pharmaceuticals and Medical Devices Agency (PDMA), local companies, BMI

Industries : Drug and Medication
Countries : Japan

Japan Patented Drug Sales, Us$bn, % Chg Y-o-y

$ 250
Industry data
January 2013

Yearly, From 2003 To 2021
By Business Monitor International
Source: Pharmaceuticals and Medical Devices Agency (PDMA), local companies, BMI

Industries : Drug and Medication
Countries : Japan

Japan Patented Drug Sales, Us$bn, 5 Year Forward Cagr, %

$ 250
Industry data
January 2013

Yearly, From January 01, 2012 To January 01, 2012
By Business Monitor International
Source: Pharmaceuticals and Medical Devices Agency (PDMA), local companies, BMI

Industries : Drug and Medication
Countries : Japan

Japan Patented Drug Sales, Us$bn, 5 Year Trailing Cagr, %

$ 250
Industry data
January 2013

Yearly, From January 01, 2012 To January 01, 2012
By Business Monitor International
Source: Pharmaceuticals and Medical Devices Agency (PDMA), local companies, BMI

Industries : Drug and Medication
Countries : Japan

Japan Patented Drug Sales, Eurbn

$ 250
Industry data
January 2013

Yearly, From 2002 To 2021
By Business Monitor International
Source: Pharmaceuticals and Medical Devices Agency (PDMA), local companies, BMI

Industries : Drug and Medication
Countries : Japan

Drug And Medication Industry in Japan : Latest Reports

Vaccines - Global Markets Package

$ 24 060
Industry report
May 2013
by Global Research & Data Services

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different countries around the world. The studies provide essential market ...

Infertility Drugs And Devices Market - Global Industry Analysis, Size, Share And Forecast, 2010 - 2017

$ 4 395
Industry report
November 2013
by Transparency Market Research

This report is an effort to identify factors, which will be the driving force for the infertility drugs and devices market and sub-markets in the next few years. The report provides an extensive analysis ...

Triple Analysis: Angiogenesis, Cancer Vaccines and Peptides

$ 5 175
Industry report
March 2013
by Bioseeker

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines and by the compound strategy of Peptides. Each of these three ...

Triple Analysis: Angiogenesis, Cancer Vacc ...

March 2013 $ 5 175

Triple Analysis: Angiogenesis, Cancer Vacc ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Angiogenesis A ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Cancer Vaccine ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Cancer Vaccine ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Cancer Vaccine ...

March 2013 $ 5 175

Triple Analysis: Breast Cancer, Angiogenes ...

March 2013 $ 5 175

Drug And Medication Industry in Japan : Latest Downloads

Drug and Medication Industry Analysis

Industry report
April 2013
53 pages

... Use internally as part of a monthly cleansing regimen for gi health antibiotic, anti-inflammatory, antibacterial, antifungal, antioxidant, anti-parasitic, antiviral, disinfectant candida cleanse ...

Drug and Medication Market Brief

Industry report
April 2013
18 pages

... Antiosteoporosic drugs - casula m, filippi a, flacco e, gambera m, manzoli l, menditto e, orlando v, piccinelli r, tragni e, catapano a. Assessment and potential determinats of compliance and persistence to anti ...

Drug and Medication : Innovation and Technology Trends

Industry report
April 2013
12 pages

... Clinical regulatory toxicology phase i clinical phase ii clinical diabetes inflammation oncology (non-cytotoxic) anti-infectives clotting disorders obesity cns nce pipeline nce pipeline tyrosine-tzd, non ...